SYDNEY--Neuren Pharmaceuticals shares gained after its U.S. partner signaled global net sales of the Daybue treatment for Rett Syndrome could reach US$700 million in 2028. Shares were recently up 8.3% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback